DeepSeek Eyes $74 Billion Valuation Ahead of Planned China IPO 
Lockheed Martin Unveils Lower-Cost Patriot ACE Interceptor to Meet Rising Air Defense Demand 
TSMC Sees Multi-Year AI Chip Demand as Arizona Expansion Reaches $265 Billion 
SpaceX Aborts Starship Test Flight as Engine Issue Delays Launch 
Tesla Stock Outlook: Strong EV Sales Boost Earnings, but AI Projects Drive Long-Term Value 
Bank of America Says These Overlooked AI Stocks Could Be the Next Winners 
NTSB Leads Investigation Into Ryanair Boeing 737 Engine Failure Over Greece 
Samsung Cuts U.S. Consumer Electronics Jobs as Headquarters Moves to Texas 
Netflix Stock Drops After Weak Q3 Outlook Overshadows Mixed Q2 Earnings 
SpaceX Eyes Pentagon AI Deal as Cloud Pricing Strategy Pressures CoreWeave 
Foxconn Wins First SpaceX AI Server Contract Worth Estimated $52 Billion 
Volvo Cars Q2 Profit Falls as Automaker Bets on EX60 EV to Drive Recovery 
Seven & i Eyes Żabka Stake in Major European Expansion Push 
KKR, AEW Seek China Property Sales as Commercial Real Estate Slump Deepens 
South Korea’s Coupang Fine Sparks U.S. Criticism, Raising Concerns Over Bilateral Ties 
Samsung Biologics has announced plans to acquire Swiss contract drug manufacturer PolyPeptide in an all-cash deal valued at approximately 1.46 billion Swiss francs ($1.81 billion), strengthening its position in the fast-growing peptide therapeutics market.
Under the proposed transaction, Samsung Biologics will offer 44.31 Swiss francs per share, representing a 6.1% premium to PolyPeptide’s closing price of 41.75 Swiss francs on Friday. The South Korean biotech company expects to launch the tender offer by the end of August, with the acquisition targeted for completion before the end of the year.
The acquisition is part of Samsung Biologics’ strategy to expand its contract development and manufacturing capabilities, particularly in peptide-based medicines. The company sees strong growth opportunities in therapies for obesity and diabetes, including GLP-1 drugs, a segment experiencing surging global demand.
PolyPeptide’s board of directors has unanimously recommended that shareholders accept the offer, signaling strong support for the transaction.
Samsung Biologics also said it intends to acquire all remaining shares after the tender offer through a squeeze-out process, allowing it to delist PolyPeptide from the SIX Swiss Exchange and operate the company as a wholly owned subsidiary.
The deal already has the backing of Draupnir Holding, PolyPeptide’s largest shareholder, which controls approximately 55.65% of the company. Draupnir confirmed it will tender all of its shares into Samsung Biologics’ offer.
Earlier this year, PolyPeptide disclosed that Draupnir was reviewing strategic options for its majority stake. Draupnir’s parent organization, the Cryosphere Foundation, has previously been linked to Swedish billionaire Frederik Paulsen.
If completed, the acquisition would significantly enhance Samsung Biologics’ manufacturing portfolio and strengthen its presence in the rapidly expanding global market for peptide-based pharmaceutical ingredients. The move also reflects growing competition among contract drug manufacturers seeking to capitalize on increasing demand for innovative biologic and metabolic disease treatments.
